Volume | 324,371 |
|
|||||
News | - | ||||||
Day High | 0.95 | Low High |
|||||
Day Low | 0.91 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
HOOKIPA Pharma Inc | HOOK | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
0.94 | 0.91 | 0.95 | 0.9302 | 0.9179 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
1,039 | 324,371 | $ 0.9277853 | $ 300,947 | - | 0.41 - 2.01 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:54:14 | 2 | $ 0.945 | USD |
HOOKIPA Pharma Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
78.07M | 83.95M | - | 20.13M | -81.58M | -0.97 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
HOOKIPA Pharma News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical HOOK Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.795 | 1.03 | 0.7787 | 0.9107228 | 1,338,845 | 0.15 | 18.87% |
1 Month | 0.733101 | 1.03 | 0.70 | 0.8432919 | 1,347,721 | 0.2119 | 28.90% |
3 Months | 0.6701 | 1.03 | 0.60 | 0.7912499 | 812,204 | 0.2749 | 41.02% |
6 Months | 0.44 | 1.13 | 0.41871 | 0.7946564 | 1,651,997 | 0.505 | 114.77% |
1 Year | 1.11 | 2.01 | 0.41 | 0.9006626 | 1,243,412 | -0.165 | -14.86% |
3 Years | 13.65 | 20.00 | 0.41 | 1.96 | 1,225,945 | -12.71 | -93.08% |
5 Years | 14.00 | 20.00 | 0.41 | 2.40 | 768,578 | -13.06 | -93.25% |
HOOKIPA Pharma Description
HOOKIPA Pharma Inc is a clinical stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. It uses off-the-shelf technologies, VaxWave and TheraT, to elicit directly within patients a response of antigen-specific killer T cells and antibodies. |